

INSTITUTIONAL BIOSAFETY COMMITTEE MINUTES  
Recombinant DNA(RM)  
*Meeting #273*  
*Tuesday, February 10, 2026*  
**Hybrid - In Person Location BSRB S3.8003ab - 1:00 PM**

**Members Present**

Xue Hao, Assistant Professor  
Bisrat Godefay Debeb, Associate Professor  
Kwong K Wong, Professor  
Izabela Fokt, Assistant Professor  
Marcos Roberto Estecio, Professor  
Tora D Ogunmakin, Assoc Dir, Ambulatory Nursing  
Xiang-Yang Han, Professor  
Shilpa S. Dhar, Assistant Professor  
Dina H Ray, Research Nurse Manager  
Zahid H Siddik, Professor  
Erica J Moore, Assistant Professor  
Pijus K Mandal, Institute Research Scientist  
Chavaun H LeBlanc, Mgr, Environ Health & Safety  
Niki M. Zacharias Millward, Associate Professor  
Hai T Tran, Associate Professor  
Hesham Amin, Professor  
Guang Peng, Professor  
Guocan Wang, Associate Professor  
Rajneesh Pathania, Assistant Professor  
Krithika Srinivasan, Assistant Professor  
Jody Swain, Associate Professor  
Yang Lu, Supv, Laboratory & Research  
Taiping Chen, Professor  
Vidya Gopalakrishnan, Associate Professor

**Members Absent**

Linette M Leadon, Dir, EHS Sustain & Emerg Mgmt  
Humam N Kadara, Professor  
Pramod N Nehete, Professor

**Community Members Present**

**Others Present**

Robert Plant, Safety Specialist  
Allyson Wakefield, Program Manager  
Madeline McAllister, Compliance Analyst  
Cheryl Smith, Safety Specialist  
Tekchheng Tam, Safety Specialist  
Garlen F Yeager Jr, Principal Safety Specialist  
Joseph E Jacobs, Safety Specialist  
Brittany N Kleb, Assoc Dir, Institutional Compl  
Edith Plants Paris, Compliance Analyst  
David A Imperial, Safety Specialist  
Marivonne Rodriguez, Principal Safety Specialist  
Dana Blackburn, Compliance Analyst  
Nastassia Harper, Safety Specialist

## Others Absent

### 1. APPROVAL OF THE PAST MEETING MINUTES

Meeting	Votes-Yes	Votes-No	Votes-Abstain	Votes-Recuse
IBC Recombinant meeting on Tuesday, January 13, 2026	21	0	4	0

### 2. CONFLICT OF INTEREST RECUSAL

Attendee	Project	Comment
Vidya Gopalakrishnan	RM00001918-RN01_AM3	Dr. Gopalakrishnan is the PI of this non-administrative modification.
Vidya Gopalakrishnan	RM00000443-RN02_AM1	Dr. Gopalakrishnan is the PI of this non-administrative modification.
Marcos Roberto Estecio	RM00000418-RN02_AM2	Dr. Estecio is the PI of this administrative modification.
Vidya Gopalakrishnan	RM00000959-RN02_AM1	Dr. Gopalakrishnan is the PI of this non-administrative modification.
Vidya Gopalakrishnan	RM00001584-RN01_AM1	Dr. Gopalakrishnan is the PI of this non-administrative modification.
Vidya Gopalakrishnan	RM00001327-RN02_AM1	Dr. Gopalakrishnan is the PI of this non-administrative modification.
Vidya Gopalakrishnan	RM00001584-RN02_AM1	Dr. Gopalakrishnan is the PI of this non-administrative modification.
Humam N Kadara	RM00003627-RN01_AM9	Dr. Kadara is the PI of this non-administrative modification.

### 3. REPORT OF THE ADVERSE EVENTS

Krithika Srinivasan, M.D.; Assistant Professor, Infections Diseases - Nothing to report.

### 4. REPORT OF THE SAFETY COMMITTEE

Chavaun LeBlanc, M.S.; Mgr, Environ Health & Safety, Fac Mgt EHS EPP Lab & OHS - Nothing to report.

### 5. REPORT OF RECOMBINANT DNA (RM) SUBCOMMITTEE

Marcos Roberto Estecio, Ph.D.; Professor, Epigenet & Mol Carcinogenesis

### 6. NEW PROTOCOLS

#### **BSL 1: NEW PROTOCOLS**

There are no new protocols to review for this meeting.

#### **NEW TRANSGENIC ANIMAL PROTOCOLS:**

There are no new protocols to review for this meeting.

#### **BSL 2: NEW PROTOCOLS**

Disposition	Votes For	Votes Against	Votes Abstain	Votes-Recuse
Approved With Contingencies	25	0	0	0
Investigator :			Issam I Raad	
Document No. :			RM00008575-RN00	
NIH Guidelines Category :			NA	
Agents :				
<b>Microbial Agents</b>				
<b>Name</b>			<b>Administered to Animals in Vivo</b>	
Escherichia Coli (MB #2839)			No	

**BSL 2: NEW PROTOCOLS**

**Microbial Agents**

Klebsiella Pneumoniae (MB #4357)  
Staphylococcus Aureus (MDA #120)

No  
No

**Room Numbers**

**Room No.**

Y6.5306

Biosafety Level :

Meeting Notes :

**Description**

Inactive Area - Empty

BSL2

The objective of this protocol is to further develop novel antimicrobial technologies in the Raad Lab. This will be done by assessing the ability of these technologies in either the prevention or eradication of microbial biofilm by gram-positive and gram-negative bacteria obtained from the CDC and FDA Antibiotic Resistance Isolate Bank. Strains of E. coli, S. aureus, and K. pneumoniae will be used. These are clinical isolates and are often more virulent than laboratory-safe strains, requiring strict adherence to BSL-2 practices.

---

<b>Disposition</b>	<b>Votes For</b>	<b>Votes Against</b>	<b>Votes Abstain</b>	<b>Votes-Recuse</b>
Approved With Contingencies	25	0	0	0

Investigator :

Chandra Bartholomeusz

Document No. :

[RM00004881-RN01](#)

NIH Guidelines Category :

III-D-1-a.

Agents :

**Viral Systems**

**Virus System**

Lentivirus

**Virus Administered to Animals**

No

**Backbones**

pLKO.1

Lentivirus

No

pGFP-V-RS

**Cell Lines**

**Cell Line**

Breast Cancer

**Cell Lines Administered to Animals in Vivo**

Yes

**Microbial Agents**

**Name**

E.coli DH5alpha

**Administered to Animals in Vivo**

No

**Room Numbers**

**Room No.**

Z12.4031C

S1.8465

Biosafety Level :

Meeting Notes :

**Description**

Tissue Culture Facility

Animal Facilities

BSL2

This protocol will study the role of EGR1 in TNBC. The investigator will use lentiviral systems for knockdown and overexpression experiments in cell lines. The modified cell lines will be administered to animals in vivo. ACUF is current. Among other contingencies, the investigators need to clarify whether all lentiviral backbones required for the study are listed.

---

<b>Disposition</b>	<b>Votes For</b>	<b>Votes Against</b>	<b>Votes Abstain</b>	<b>Votes-Recuse</b>
--------------------	------------------	----------------------	----------------------	---------------------

**BSL 2: NEW PROTOCOLS**

Approved With Contingencies	25	0	0	0
-----------------------------	----	---	---	---

Investigator : Van Karlyle Morris  
 Document No. : [RM00004940-RN01](#)  
 NIH Guidelines Category : III-C-1.  
 Agents :

**Non Viral Systems**

<b>Technical Name</b>	<b>Is Whole Animal Used as Host</b>
RO7198457	No

**Room Numbers**

<b>Room No.</b>	<b>Description</b>
R10.1878B	Pharmacy
R1.1007	Healthcare Treatment/Examination
B1.4409B	Pharmacy

Biosafety Level : BSL2

Meeting Notes : This Phase II multi-site study aims to compare the efficacy of mRNA therapeutic vaccine to watchful waiting in patients with resected stage II or stage III colorectal cancer who are ctDNA positive following resection. The mRNA vaccine, which contains up to 20 different tumor-specific neoantigens specific to the individual's tumor, will be created offsite and then shipped to MD Anderson. IRB protocol is approved.

<b>Disposition</b>	<b>Votes For</b>	<b>Votes Against</b>	<b>Votes Abstain</b>	<b>Votes-Recuse</b>
Approved With Contingencies	25	0	0	0

Investigator : Mahmoud Gaballa  
 Document No. : [RM00008594-RN00](#)  
 NIH Guidelines Category : III-C-1.  
 Agents :

**Viral Systems**

<b>Virus System</b>	<b>Virus Administered to Animals</b>	<b>Backbones</b>
Lentivirus	No	A third generation, self-inactivating lentiviral expression vector

**Cell Lines**

<b>Cell Line</b>	<b>Cell Lines Administered to Animals in Vivo</b>
Peripheral blood mononuclear cells (PBMCs)	No

**Room Numbers**

<b>Room No.</b>	<b>Description</b>
P14.3140	Diagnostic Support Laboratory Service
P14.2910	Diagnostic Service Laboratory
G15.3433	Patient Bedroom

Biosafety Level : BSL2

Meeting Notes : AstraZeneca Pharmaceuticals supported Phase III open-label randomized, multicenter trial comparing AZD0120 dual-targeting autologous chimeric antigen receptor T-cell (CAR-T) therapy vs standard regimens in participants with relapsed refractory multiple myeloma. Apheresis will be performed

**BSL 2: NEW PROTOCOLS**

within 6 days from randomization. AZD0120 will be generated from T cells selected from the apheresis. CAR-T cells will be manufactured at the sponsor's site and shipped back to MD Anderson. Pending IRB approval.

<b>Disposition</b>	<b>Votes For</b>	<b>Votes Against</b>	<b>Votes Abstain</b>	<b>Votes-Recuse</b>
Approved With Contingencies	25	0	0	0

Investigator : Gregory Friedman  
 Document No. : [RM00008671-RN00](#)  
 NIH Guidelines Category : III-D-4-b.  
 Agents :

**Viral Systems**

<b>Virus System</b>	<b>Virus Administered to Animals</b>	<b>Backbones</b>
Adeno-associated virus (AAV)	Yes	pAAV-CAG

**Room Numbers**

<b>Room No.</b>	<b>Description</b>
MOD1.015b	Tissue Culture Facility
MOD1.015a	Flex Wet Lab
PPB1.483	Animal Facilities
PPB1.489	Animal Facilities

Biosafety Level : BSL2

Meeting Notes : The goal of this research project is to evaluate a novel gene delivery method using adeno-associated virus (AAV), to express immune related protein which help immune cells recognition and interact with brain tumor cells. The vectors will be administered into the lateral ventricles of mice to assess vector delivery efficacy, transgene expression, and immune cell interactions with tumor cells in vivo. Following AAV administration, transgene expression and distribution will be monitored using molecular and biochemical assays. Tumor burden and disease progression will be assessed using bioluminescence imaging and survival analysis. The ACUF does not currently describe in vivo AAV work, and no amendment was available at time of review.

<b>Disposition</b>	<b>Votes For</b>	<b>Votes Against</b>	<b>Votes Abstain</b>	<b>Votes-Recuse</b>
Approved With Contingencies	25	0	0	0

Investigator : Hussein Tawbi  
 Document No. : [RM00008639-RN00](#)  
 NIH Guidelines Category : III-C-1.  
 Agents :

**Non Viral Systems**

<b>Technical Name</b>	<b>Is Whole Animal Used as Host</b>
mRNA-4359	No

**Room Numbers**

<b>Room No.</b>	<b>Description</b>
B1.4392	Multi person office
R9.2194	Examination

**BSL 2: NEW PROTOCOLS****Room Numbers**

ACB8.2043

P2.3082A

B1.4409B

Biosafety Level :

Meeting Notes :

IV Prep Room (Pharmacy)

IV Prep Room (Pharmacy)

Pharmacy

BSL2

The primary objective of this Phase 1/2 study is to assess the safety, tolerability, and antitumor activity of mRNA 4359 administered via intramuscular injection as monotherapy or in combination with systemic immune checkpoint inhibitors in patients with advanced solid tumors. The drug product consists of messenger RNA encoding immunogenic IDO1 and PD L1 peptides. IRB approval is pending.

<b>Disposition</b>	<b>Votes For</b>	<b>Votes Against</b>	<b>Votes Abstain</b>	<b>Votes-Recuse</b>
Approved With Contingencies	25	0	0	0

Investigator :

Yago Nieto

Document No. :

[RM00008474-RN00](#)

NIH Guidelines Category :

III-C-1.

Agents :

**Viral Systems****Virus System**

Retrovirus [for CAR into NK]

**Virus Administered to Animals**

No

**Backbones**

pSFG4

**Cell Lines****Cell Line**

Myeloid cell line (UAPC)

Natural Killer (NK) cell

PG13 packaging cell line

293T

**Cell Lines Administered to Animals in Vivo**

No

No

No

No

**Room Numbers****Room No.**

P14.2910

Z5.2040

Z5.2038

Z5.2042

R2.2346

R10.1878B

ACB8.2046

Biosafety Level :

Meeting Notes :

**Description**

Diagnostic Service Laboratory

Research/Non-Class Laboratory- Wet Lab

Research/Non-Class Laboratory- Wet Lab

Research/Non-Class Laboratory- Wet Lab

Pharmacy

Pharmacy

Chemo IV Prep Room (Pharmacy)

BSL2

The goal of this clinical protocol is to determine the safety, tolerability, maximum tolerated dose, optimal cell dose, and antitumor activity of CD70 CAR NK cells in patients with relapse/refractory lymphoid malignancies. Commercially sourced replication incompetent viral particles will be used to transduce cord blood NK cells with retroviral vector (pSFG4) encoding CD70-CAR in vitro. Pending IRB consent review and approval.

<b>Disposition</b>	<b>Votes For</b>	<b>Votes Against</b>	<b>Votes Abstain</b>	<b>Votes-Recuse</b>
--------------------	------------------	----------------------	----------------------	---------------------

**BSL 2: NEW PROTOCOLS**

Approved With Contingencies	25	0	0	0
-----------------------------	----	---	---	---

Investigator : Samer Srour  
 Document No. : [RM00004896-RN01](#)  
 NIH Guidelines Category : III-C-1.  
 Agents :

**Non Viral Systems**

<b>Technical Name</b>	<b>Is Whole Animal Used as Host</b>
pCLS24046, pCLS24048, pCLS24042, pCLS24044	No

**Viral Systems**

<b>Virus System</b>	<b>Virus Administered to Animals</b>	<b>Backbones</b>
Lentiviral vectors	No	The lentiviral transfer vector proprietary to Lentigen, which drives expression of the CD70CAR transgene via the human EF1alpha promoter, is a self-inactivating (SIN), 3rd generation transfer vector, and includes the mutant WPRE.

**Cell Lines**

<b>Cell Line</b>	<b>Cell Lines Administered to Animals in Vivo</b>
Human PBMC	No

**Room Numbers**

<b>Room No.</b>	<b>Description</b>
P14.2910	Diagnostic Service Laboratory
P14.3140	Diagnostic Support Laboratory Service

Biosafety Level : BSL2

Meeting Notes : This clinical protocol aims to assess safety and tolerability at increasing dose levels of ALLO-316 in successive cohorts of subjects with advanced or metastatic ccRCC. 1. Drug combinations include fludarabine/cyclophosphamide and ALLO-647. ALLO-316 is an allogeneic TRAC/CD52-knockout CAR T cell therapy targeting CD70. ALLO-647 is a novel human IgG1 monoclonal antibody (mAb) that recognizes the human CD52 antigen. ALLO-316 will be manufactured at the sponsor's site and shipped to the GMP Lab. IRB protocol is approved.

<b>Disposition</b>	<b>Votes For</b>	<b>Votes Against</b>	<b>Votes Abstain</b>	<b>Votes-Recuse</b>
Approved With Contingencies	24	0	1	0

Investigator : Steven Millward  
 Document No. : [RM00004942-RN01](#)  
 NIH Guidelines Category : III-D-3-a.  
 Agents :

**Non Viral Systems**

<b>Technical Name</b>	<b>Is Whole Animal Used as Host</b>
pENTR223	No
pCMV	No

## **BSL 2: NEW PROTOCOLS**

### **Viral Systems**

<b>Virus System</b>	<b>Virus Administered to Animals</b>	<b>Backbones</b>
Lentivirus/shRNA	No	pLKO
Lentiviral	No	FUW
Lentivirus/shRNA	No	pTRIPZ
Lentivirus	No	pLenti, CRISPR/ Cas9
Lentivirus/shRNA	No	pGIPZ
Lentivirus	No	pCLIP

### **Cell Lines**

<b>Cell Line</b>	<b>Cell Lines Administered to Animals in Vivo</b>
537 MELanoma PAPSS2 rescued (537 MEL PAPSS2RES)	No
NeuroChirurgie Eppendorf-Glioma 59 PAPSS2 rescued (G59 PAPSS2RES)	No
HCT 116 colon cancer cells	No
Henrietta Lacks cells, Human papillomavirus-related endocervical adenocarcinoma (HeLa)	No
SK-MEL-28 Cutaneous melanoma (SK-MEL-28)	No
SK-MEL-2 Melanoma (SK-MEL-2)	No
NeuroChirurgie Eppendorf-Glioma 59 PANK1 rescued (G59 PANK1RES)	No
537 MELanoma KIF20B rescued (537 MEL KIF20BRES)	No
NeuroChirurgie Eppendorf-Glioma 59 (G59)	No
293T embryonic kidney cells (HEK 293T)	No
D-423MG Glioblastoma (D423)	No
U-87MG ATCC Glioblastoma (U87)	No
U-373MG ATCC Astrocytoma (U373)	No
NeuroChirurgie Eppendorf-Glioma 59 KIF20B rescued (G59 KIF20BRES)	No
SK-MEL-5 Cutaneous melanoma (SK-MEL-5)	No
537 MELanoma (537 MEL)	No
537 MELanoma PANK1 rescued (537 MEL PANK1RES)	No
SW1088 Astrocytoma (SW1088)	No

### **Microbial Agents**

<b>Name</b>	<b>Administered to Animals in Vivo</b>
DH5-alpha E. coli	No

### **Room Numbers**

<b>Room No.</b>	<b>Description</b>
3SCR4.3511	Tissue Culture Facility
Biosafety Level :	BSL2
Meeting Notes :	This protocol covers the editing of cell lines using non-viral and lentiviral plasmids to overexpress, knockdown, or knockout multiple genes of interest in cancer. The study does not include work in animals, and human subjects are also not part of the study.

---

<b>Disposition</b>	<b>Votes For</b>	<b>Votes Against</b>	<b>Votes Abstain</b>	<b>Votes-Recuse</b>
Approved With Contingencies	25	0	0	0

**BSL 2: NEW PROTOCOLS**

Investigator : Brian D Badgwell  
 Document No. : [RM00008503-RN00](#)  
 NIH Guidelines Category : III-C-1.  
 Agents :

**Viral Systems****Virus System**

Retrovirus

**Virus Administered to Animals**

No

**Backbones**

pSFG (MMLV retroviral)

**Cell Lines****Cell Line**

Myeloid cell line (UAPC)

Natural Killer (NK) cell

**Cell Lines Administered to Animals in Vivo**

No

No

**Room Numbers****Room No.**

P14.2910

Z5.2042

R2.2346

R10.1878B

Z5.2040

Z5.2038

R1.1007

P14.3063

ACB8.2046

P14.3059

B1.4409B

**Description**

Diagnostic Service Laboratory

Research/Non-Class Laboratory- Wet Lab

Pharmacy

Pharmacy

Research/Non-Class Laboratory- Wet Lab

Research/Non-Class Laboratory- Wet Lab

Healthcare Treatment/Examination

Diagnostic Service Laboratory

Chemo IV Prep Room (Pharmacy)

Diagnostic Service Laboratory

Pharmacy

Biosafety Level :

BSL2

Meeting Notes :

This protocol is a first-in-human dose escalation and dose expansion study evaluating the safety and preliminary efficacy of TGFBR2 KO TROP2-CAR-NK cells in combination with Zolbetuximab for patients with gastric cancer with peritoneal metastases. The CAR-NK cells will be produced at MDACC GMP using commercially sourced retroviruses. Patients will be evaluated for cfDNA clearance and persistence of the CAR-NK cells. IRB is pending approval.

Disposition	Votes For	Votes Against	Votes Abstain	Votes-Recuse
Approved With Contingencies	25	0	0	0

Investigator : Warren C Fiskus  
 Document No. : [RM00008627-RN00](#)  
 NIH Guidelines Category : III-D-1-a.  
 Agents :

**Non Viral Systems****Technical Name**

BaEV-LV

**Is Whole Animal Used as Host**

No

**Viral Systems****Virus System**

lentivirus

**Virus Administered to Animals**

No

**Backbones**

lenticrisprV2

## **BSL 2: NEW PROTOCOLS**

### **Viral Systems**

Lentivirus	No	pLKO1.puro
lentivirus	No	pLCG (hU6-sgRNA-EFSSpCas9-P2A-GFP)- sgBRD4.N
lentivirus	No	SOP (pRRL-SFFV-Tir1-3xMYC-tag-T2A-Puro)
Lentivirus	No	pLenti_sgRNA_EFS_GFP
lentivirus	No	pLenti-dCas9-KRAB-blast
Lentivirus	No	pHIV-Luc-ZsGreen
lentivirus	No	plenti-CMV vector
lentivirus	No	SO-blue (pRRL-SFFV-Tir1-3xMYC-tag-T2A-EBFP2)
lentivirus	No	pLPG-AID-BRD4 (5'HA-BlastR-P2A-V5-AID-spacer-3'HA-hPGK-eGFP)

### **Cell Lines**

#### **Cell Line**

leukemia cell lines  
Human Leukemia cells  
32D bone marrow cells  
Mantle Cell leukemia/lymphoma  
Pro B cells (Ba/F3)  
Human embryonic kidney (HEK293T) cells

#### **Cell Lines Administered to Animals in Vivo**

Yes  
Yes  
No  
Yes  
No  
No

### **Microbial Agents**

#### **Name**

E. coli Sure2  
E. coli Stbl3

#### **Administered to Animals in Vivo**

No  
No

### **Room Numbers**

#### **Room No.**

T6.3932  
S1.8464  
T6.3932A  
S1.8465

#### **Description**

Research/Non-Class Laboratory- Wet Lab  
Animal Facilities  
Tissue Culture Facility  
Animal Facilities

Biosafety Level :

BSL2

Meeting Notes :

The PI will utilize cultured human AML cell lines to determine the effects of RNAi/CRISPRmediated depletion of gene expression of multiple genes with relevance to cancer. The impact of this on the anti-leukemia activity of new targeted chemical agents will be determined, as examples BET protein antagonist, FLT3 antagonists, EZH2 antagonist, and other agents. Viral and non-viral plasmids will be used with cell lines in vitro, and some of the lines will be administered to animals in vivo. ACUF protocols are current. An IRB protocol is included due to collection of leukemia cells from patients.

---

<b>Disposition</b>	<b>Votes For</b>	<b>Votes Against</b>	<b>Votes Abstain</b>	<b>Votes-Recuse</b>
Approved With Contingencies	25	0	0	0

Investigator :

Neal Akhave

Document No. :

RM00008522-RN00

## **BSL 2: NEW PROTOCOLS**

NIH Guidelines Category :

III-C-1.

Agents :

### **Non Viral Systems**

#### **Technical Name**

DNA pAC/emm55 in TE Buffer

#### **Is Whole Animal Used as Host**

No

### **Room Numbers**

#### **Room No.**

P3.3027

B1.4392A

R2.1740

#### **Description**

Patient Bedroom

Pharmacy

Public Corridor

Biosafety Level :

BSL2

Meeting Notes :

The primary aim of this study is to compare the objective response rate in participants with advanced or metastatic Merkel cell carcinoma treated with intralesional IFx Hu2.0 followed by pembrolizumab versus placebo followed by pembrolizumab. The agent is a recombinant plasmid expression vector containing a modified Streptococcus pyogenes serotype M55 cell surface M protein antigen. The sponsor will ship the investigational product frozen to MD Anderson Cancer Center. IRB protocol approval is pending.

---

## **BSL 3: NEW PROTOCOLS**

There are no new protocols to review for this meeting.

### **7. MODIFICATIONS WITH NEW BSL2/BSL3 AGENTS/PROCEDURES/PI CHANGE**

<b>Disposition</b>	<b>Votes For</b>	<b>Votes Against</b>	<b>Votes Abstain</b>	<b>Votes-Recuse</b>
Approved With Contingencies	25	0	0	0

Investigator :

Farhad R. Danesh

Document No. :

RM00001869-RN01\_AM6

NIH Guidelines Category :

III-D-3-a.

Agents :

### **Non Viral Systems**

#### **Technical Name**

piggybac CMV-GFP

pGEM-T-Easy

pcDNA3.1

#### **Is Whole Animal Used as Host**

No

No

No

### **Viral Systems**

#### **Virus System**

Lentivirus

Lentivirus

Retrovirus

#### **Virus Administered to Animals**

No

No

No

#### **Backbones**

PLKO.1

pdCas9/VP64/KRAB and its derivatives

pBABE; MSCV

### **Cell Lines**

#### **Cell Line**

293T (human helper cell for Lenti-virus production)

mouse mesangial cells

human mesangial cells

NIH-3T3 fibroblast cell

#### **Cell Lines Administered to Animals in Vivo**

No

No

No

No





## Cell Lines

[REDACTED]	No
[REDACTED]	No
[REDACTED]	Yes
[REDACTED]	No
[REDACTED]	No
[REDACTED]	No
[REDACTED]	No
[REDACTED]	No
[REDACTED]	No
[REDACTED]	No
[REDACTED]	No
[REDACTED]	No
[REDACTED]	No
[REDACTED]	No
[REDACTED]	No
[REDACTED]	No
[REDACTED]	No
[REDACTED]	No
[REDACTED]	No
[REDACTED]	No

## Microbial Agents

<b>Name</b>	<b>Administered to Animals in Vivo</b>
[REDACTED]	No
Biosafety Level :	BSL2
Meeting Notes :	This amendment added [REDACTED] to the protocol.

---

Disposition	Votes For	Votes Against	Votes Abstain	Votes-Recuse
Approved With Contingencies	24	0	1	0

Investigator : Vidya Gopalakrishnan  
Document No. : [RM00001918-RN01\\_AM3](#)  
NIH Guidelines Category : III-D-1-a.  
Agents :

## Non Viral Systems

<b>Technical Name</b>	<b>Is Whole Animal Used as Host</b>
pGL4.20	No
pX458-U6-chimeric BB(+85)-CBh-NLS-hSpCsn1-2A-GFP	No

## Viral Systems

Virus System	Virus Administered to Animals	Backbones
Lentivirus	No	Phage-ef1a-ccdb-ires-Flu2-GFP
Retrovirus	No	mimR1-Flu2-mkate2
Lentivirus	No	Phage-ef1a-ccdb-ires-puro
Lentivirus	No	pLTR-RD114A
Lentivirus	No	Phage-ef1a-ccdb-ires-Renilla-GFP
Lentivirus	No	Phage-ef1a-ccdb-ires-mkate2
Retrovirus	No	mipR1-Flu2-puro
Lentivirus	No	pHCMV_Bless
Lentivirus	No	P-VSVG

## Viral Systems

Lentivirus	No	pGIPZ
Lentivirus	No	Phage-ef1a-ccdb-ires-Flu2-mkat2
Lentivirus	No	Phage-ef1a-ccdb-ires-GFP

## Cell Lines

### Cell Line

Brain Cancer	Yes
Neural Stem Cells and Progenitors	Yes
293T cell (embryonic kidney of Homo sapiens)	No

### Cell Lines Administered to Animals in Vivo

## Microbial Agents

### Name

E.coli, DH5a	No
E. coli k-12	No
Biosafety Level :	BSL2
Meeting Notes :	Updated IACUC protocol number due to renewal.

### Administered to Animals in Vivo

---

<b>Disposition</b>	<b>Votes For</b>	<b>Votes Against</b>	<b>Votes Abstain</b>	<b>Votes-Recuse</b>
Approved With Contingencies	25	0	0	0

Investigator :

Dihua Yu

Document No. :

[RM00000653-RN02\\_AM13](#)

NIH Guidelines Category :

III-D-4-b.

Agents :

## Non Viral Systems

### Technical Name

esiRNA	No
pCMV6	No
pMD2.G	No
pBK-CMV	Yes
psPAX2	No

### Is Whole Animal Used as Host

## Viral Systems

### Virus System

Lentivirus	No	Backbones pMD2.6 and psPAX2 as part of the package system. PLKO, PGIPZ, PTRIPZ and other backbones suitable for shRNA delivery, pLentiCRISPR v2 and TLCV2 for CRISPR cas9 mediated gene knockout
Lentivirus	Yes	pMD2.6 and psPAX2 as part of the package system. pLVX, pLOC, pLKO, pGIPZ , pLenti6.3, pLOVE, pCDH, pTRIPZ, PLX304
retrovirus	No	pWZL

### Virus Administered to Animals

## Cell Lines

### Cell Line

Mouse T cells (including spleen T cells, tumor infiltrating T cells, and T cells from tumor draining lymph nodes)	Yes
murine spleen T cells (including OT-1/OT-2 cells)	Yes
murine dendritic cell line DC2.4	Yes

### Cell Lines Administered to Animals in Vivo

## Cell Lines

breast cancer	Yes
mammary tumor cell	Yes
packaging cell for lenti- or retrovirus production	No
fibroblast cells	Yes
human monocytes derived dendritic cells (MoDCs)	No
breast cancer PDX lines and derivative sublines (including WHIM3 cells)	Yes
myeloid cells (bone marrow derived macrophages or dendritic cells)	Yes
mouse melanoma cell lines	Yes
pancreatic cancer cell	Yes
packaging cell line 293T or HEK293	No
lung cancer cell lines	Yes
pancreatic cancer cell	Yes

## Microbial Agents

<b>Name</b>	<b>Administered to Animals in Vivo</b>
E.coli DH5 $\alpha$	No
Biosafety Level :	BSL2
Meeting Notes :	Two new IACUC protocols were added, due to the inclusion of work with mouse T cells. The PI needs to be added to one of the new IACUC.

---

<b>Disposition</b>	<b>Votes For</b>	<b>Votes Against</b>	<b>Votes Abstain</b>	<b>Votes-Recuse</b>
Approved	25	0	0	0

Investigator :	Gabriel Pagnotti
Document No. :	<a href="#">RM00006218-RN00_AM8</a>
NIH Guidelines Category :	III-D-1-a.
Agents :	

## Non Viral Systems

<b>Technical Name</b>	<b>Is Whole Animal Used as Host</b>
pcDNA	No
pHA-SRI	No
pIRES- 2DsRed1	No
pIRES-puro3	No
pIRES2-AcGFP1	No
pcDNA 3.2	No
pCMV	No
pHA-PI4K2A	No
pIES-neo3	No
pIRES-hyg3	No

## Viral Systems

<b>Virus System</b>	<b>Virus Administered to Animals</b>	<b>Backbones</b>
Lentivirus	No	pLKO.1

## Cell Lines

<b>Cell Line</b>	<b>Cell Lines Administered to Animals in Vivo</b>
Medullary thyroid cancer MZCRC1	Yes
Human tissue samples	No

## Cell Lines

Mouse anaplastic thyroid cancer (ATC) cell line	Yes
Breast cancer Hs578T	No
Melanoma 1205Lu	No
Mouse cell line MLO-Y4	No
Breast Cancer SUMM44PE	Yes
Human blood samples	No
Prostate cancer VCap	Yes
Prostate cancer LuCap23.1	Yes
Prostate cancer C4-2B	Yes
Mouse cancer cell line B16-F1	No
Multiple myeloma JLN3	Yes
Breast Cancer MDA-MB-134	Yes
Prostate cancer MDA-PCa-2b	Yes
Medullary thyroid cancer MTC-TT	Yes
Rat cancer cell line UMR106	No
Prostate cancer PC-3	Yes
HEK293T human embryonic kidney cells	No
Prostate cancer C4	Yes
Breast cancer T47-D	No
Breast cancer ZR-75-1	No
Lung cancer RWGT2	No
Mouse cell line C3H10T1/2	No
Multiple myeloma 5TGM1	Yes
Mouse cancer cell line 4T1	Yes
Lung cancer A549	No
Breast cancer MCF10A	No
Breast cancer MCF-7	Yes
Mouse cancer cell line B16-cOVA	No
Prostate cancer DU145	Yes
Hepatocarcinoma HepG2	No
Mouse cell line NIH-3T3	No
Prostate cancer C4-2	Yes
H1299 human NSCLC	No
Breast cancer MDA-MB-435s	No
Prostate cancer LnCaP	Yes
Breast cancer MDA-MB-231	Yes

## Microbial Agents

Name	Administered to Animals in Vivo
E.coli XL1	No
E. coli K12 JM109	No
E.coli HB101	No

Biosafety Level : BSL2

Meeting Notes : The amendment adds two breast cancer cell lines to the study. ACUFs were updated accordingly, and personnel was updated as well.

---

Disposition	Votes For	Votes Against	Votes Abstain	Votes-Recuse
-------------	-----------	---------------	---------------	--------------

Approved With Contingencies 24 0 1 0

Investigator : Vidya Gopalakrishnan  
 Document No. : RM00000443-RN02\_AM1  
 NIH Guidelines Category : III-D-1-a.  
 Agents :

**Non Viral Systems**

Technical Name	Is Whole Animal Used as Host
pcDNA3.1/ND2/REST	No
pcDNA3-myc3-p27	No
HA-ubiquitin	No
pcDNA3-myc-Skp2	No
pBeta-TRCP	No
pcDNA3.1/ND2/REST	No
Flag-HA-USP37 C234S (mut)	No
Flag-HA-USP37	No
Flag-HA-USP1	No
ffluc/mKate	No

**Viral Systems**

Virus System	Virus Administered to Animals	Backbones
Lentivirus	No	pLX304-PRMT8
Retrovirus	No	Migr1-REST-VP16;Migr1-REST C-term mut;Migr1-REST N-term mut
Lentivirus	No	pRS117-CB13K-U6-sh-HTS6-UbiC-TagGFP2-2A-Puro-W
Retrovirus	No	pMSCVpuro
Retrovirus	No	Migr1 Hes1;Migr1 Hes1-WRPW;Migr1 Hes1 N-term mut;Migr1 Hes1-bHLH-Orange;Migr1-RFP
Lentiviral	No	pLKO.1 shRNA vector
Lentivirus	No	pLX304
Retrovirus	No	pDEST
Retrovirus	No	migr1-GFP; migr1-Rest-GFP; migr1-Rest-DBD-GFP
Lentivirus	No	pGIPZ lentiviral vector, shG9a, shHDAC1, shHDC2, shLSD1, shP27, shPRMT8, shRest
Lentivirus	No	pHAGE-EF1a-IRES-EGFP; pHAGE-EF1a-IRES-mkate2;pHAGE-EF1a-IRES-puro
Lentivirus	No	Puro.Cre

**Cell Lines**

Cell Line	Cell Lines Administered to Animals in Vivo
Mouse Brain Progenitor Cells	Yes
Diffuse Intrinsic Pontine Glioma	Yes
Embryonic kidney 293T cell	No
AT/RT (teratoid/rhabdoid tumor)	Yes
Medulloblastoma	Yes

## Microbial Agents

<b>Name</b>	<b>Administered to Animals in Vivo</b>
E. coli-Stb13	No
E. coli-DH10B	No
E. coli-OmniMAX™ 2 T1	No
E. coli-DH5alpha	No
Biosafety Level :	BSL2
Meeting Notes :	Updated one IACUC protocol number due to renewal, and other was removed because agents are not required in the project anymore.

---

<b>Disposition</b>	<b>Votes For</b>	<b>Votes Against</b>	<b>Votes Abstain</b>	<b>Votes-Recuse</b>
Approved With Contingencies	24	0	1	0

Investigator : Vidya Gopalakrishnan  
Document No. : [RM00000959-RN02\\_AM1](#)  
NIH Guidelines Category : III-D-1-a.  
Agents :

## Viral Systems

<b>Virus System</b>	<b>Virus Administered to Animals</b>	<b>Backbones</b>
Lentivirus	No	P-VSVG
Lentivirus	No	psPAX2
Lentivirus	No	pLKO

## Cell Lines

<b>Cell Line</b>	<b>Cell Lines Administered to Animals in Vivo</b>
Mouse neural progenitor cells	Yes
293T	No

## Microbial Agents

<b>Name</b>	<b>Administered to Animals in Vivo</b>
E.coli, DH5a	No
Biosafety Level :	BSL2
Meeting Notes :	Updated IACUC protocol number due to renewal.

---

<b>Disposition</b>	<b>Votes For</b>	<b>Votes Against</b>	<b>Votes Abstain</b>	<b>Votes-Recuse</b>
Approved	25	0	0	0

Investigator : Eugenie S Kleinerman  
Document No. : [RM00000223-RN02\\_AM1](#)  
NIH Guidelines Category : III-D-1-a.  
Agents :

## Non Viral Systems

<b>Technical Name</b>	<b>Is Whole Animal Used as Host</b>
pG5-EWS-FLI-1	No
pEGFP-C1	No
pSilencer2.1-U8 hygro plasmid	No
pBig2r-REST	No
pCDNA3.1-c-myc	No

## Viral Systems

### Virus System

lentivirus

### Virus Administered to Animals

No

### Backbones

pLV-CAPER- $\alpha$  is the cDNA into backbone pWPXL.

## Cell Lines

### Cell Line

TC71 human Ewing sarcoma cells

human neural progenitor cells

human mesenchymal cells

293T human embryonic kidney cells

human Ewing's sarcoma cells A4573

### Cell Lines Administered to Animals in Vivo

Yes

Yes

Yes

No

Yes

## Microbial Agents

### Name

E. coli DH5-alpha

Biosafety Level :

Meeting Notes :

### Administered to Animals in Vivo

No

BSL2

Added a human Ewing's sarcoma cell line to the study.

---

Disposition	Votes For	Votes Against	Votes Abstain	Votes-Recuse
Approved With Contingencies	24	0	1	0

Investigator :

Humam N Kadara

Document No. :

[RM00003627-RN01\\_AM9](#)

NIH Guidelines Category :

III-D-4-b.

Agents :

## Non Viral Systems

### Technical Name

CD24 HDR plasmid (non-viral, co-transfected for puromycin selection)

Control CRISPR/Cas9 Plasmid

CD24 CRISPR/Cas9 Knockout (KO) plasmid (guide RNA)

### Is Whole Animal Used as Host

No

No

No

## Viral Systems

### Virus System

Adeno-associated virus serotype 6

Ad5-hK14/Bgi-Cre

adenovirus Ad5mSPC-Cre-eGFP

adeno associated virus

Lentivirus

adenovirus Ad5mSPC-nteGFP

adenovirus Ad5mSPC-FLPo

adenovirus Ad5CMVFLPO

Lentivirus

Adeno-associated virus serotype 5

### Virus Administered to Animals

Yes

Yes

Yes

Yes

No

Yes

Yes

Yes

No

Yes

### Backbones

Recombinant AAV

pacAd5(9.2-100)sub360 viral backbone

pacAd5(9.2-100)sub360 viral backbone

sc-CMV

pGIPZ

pacAd5(9.2-100)sub360 viral backbone

pacAd5(9.2-100)sub360 viral backbone.

pacAd5(9.2-100)sub360 viral backbone

pLenti CMV V5-LUC

Recombinant AAV

## Cell Lines

### Cell Line

Lung cancer cell line - 344SQ

FVBW-17 (gRNA control) - Mouse lung cancer cell-line

FM471-ctrl-gRNA-GFP/luciferase cells

### Cell Lines Administered to Animals in Vivo

Yes

Yes

Yes

## Cell Lines

293FT cells	No
LKR-13 Luciferase/GFP stable cells - Mouse lung cancer cell-line	Yes
mF471-CD24-gRNA-GFP/luciferase cells - mouse lung cancer cells	Yes
LKR-13(gRNA control) - Mouse lung cancer cell-line	Yes
FVBW-17 (CD24-gRNA) - Mouse lung cancer cell-line	Yes
Fvbw 17-GFP/luciferase cells - mouse lung cancer cells	Yes
LKR-13 (Mouse lung cancer cell-line)	Yes
mF471 Luciferase/GFP stable cells - mouse lung cancer cells	Yes
mF471 - mouse lung cancer cells	Yes
LKR-13 (CD24-gRNA) - Mouse lung cancer cell-line	Yes
FVBW-17 cells (Mouse lung cancer cells)	Yes
393P (Mouse lung cancer cell-line)	Yes

## Microbial Agents

Name	Administered to Animals in Vivo
Influenza A	Yes
Sendai virus	Yes
DH5a cells	No
Biosafety Level :	BSL2
Meeting Notes :	This amendment updated IACUC protocol number.

---

Disposition	Votes For	Votes Against	Votes Abstain	Votes-Recuse
Approved With Contingencies	25	0	0	0

Investigator : Christopher Alvarez-Breckenridge  
Document No. : [RM00006080-RN00\\_AM8](#)  
NIH Guidelines Category : III-D-4-b.  
Agents :

## Non Viral Systems

Technical Name	Is Whole Animal Used as Host
pCMV-VSV-G	No
mRNA mix with nanoparticles	Yes
pCMV-dR8.91	No

## Viral Systems

Virus System	Virus Administered to Animals	Backbones
adenovirus	Yes	Delta-24 backbone (mutation of 24bp in E1A)
Lentivirus	No	pCDH-CMV-Firefly Luciferase-EF1-CopGFP

## Cell Lines

Cell Line	Cell Lines Administered to Animals in Vivo
Peripheral blood mononuclear cells	No
Chordoma cells	No
Osteosarcoma cells	Yes
GP100 specific T cell (irrelevant T cells)	Yes
M27 specific T cell (irrelevant T cells)	Yes

**Cell Lines**

lung cancer cells	Yes
Lung cancer cells	Yes
Renal cancer	Yes
Breast cancer	Yes
melanoma cells	Yes
Prostate cancer	No
Breast cancer	Yes
Prostate cancer	Yes
Parental brachyury specific T cells	Yes
CAR-NK	Yes
Chordoma cells	Yes
293T	No
Renal Cancer	Yes
Brachyury specific TCR engineered T cells	Yes
Brain metastases tissue	No
Spine primary and metastatic tumor tissue	No

**Microbial Agents**

<b>Name</b>	<b>Administered to Animals in Vivo</b>
E. coli (DH5a)	No
Biosafety Level :	BSL2
Meeting Notes :	Changed IACUC protocol number, updated IRB protocol and added new oncolytic virus to the protocol in the amendment.





<b>Disposition</b>	<b>Votes For</b>	<b>Votes Against</b>	<b>Votes Abstain</b>	<b>Votes-Recuse</b>
Approved	25	0	0	0

Investigator : Dimitrios P Kontoyiannis  
 Document No. : [RM00003639-RN01\\_AM3](#)  
 NIH Guidelines Category : NA  
 Agents :

**Cell Lines**

<b>Cell Line</b>	<b>Cell Lines Administered to Animals in Vivo</b>
	Yes

**Microbial Agents**

<b>Name</b>	<b>Administered to Animals in Vivo</b>
	Yes
	Yes
	No
	Yes
Biosafety Level :	BSL2
Meeting Notes :	The investigator updated protocol information adding new goal related to immunopathogenesis, added microbial agent for in vivo studies, and added new IACUC protocol.

<b>Disposition</b>	<b>Votes For</b>	<b>Votes Against</b>	<b>Votes Abstain</b>	<b>Votes-Recuse</b>
Approved With Contingencies	25	0	0	0

Investigator : Yuan Pan

Document No. :

RM00005849-RN00\_AM61

NIH Guidelines Category :

III-D-4-b.

Agents :

**Non Viral Systems**

**Technical Name**

[Redacted]

**Is Whole Animal Used as Host**

No  
No  
No  
No

**Viral Systems**

**Virus System**

**Virus Administered to Animals**

**Backbones**

[Redacted]

Yes  
Yes  
Yes  
Yes  
No  
Yes  
Yes  
No  
Yes  
Yes  
Yes  
No  
No  
Yes  
Yes  
No  
Yes  
No  
No  
No  
Yes

[Redacted]



**Viral Systems**

[REDACTED]	Yes	[REDACTED]
[REDACTED]	No	[REDACTED]
[REDACTED]	Yes	[REDACTED]
[REDACTED]	No	[REDACTED]
[REDACTED]	Yes	[REDACTED]
[REDACTED]	Yes	[REDACTED]
[REDACTED]	No	[REDACTED]
[REDACTED]	Yes	[REDACTED]
[REDACTED]	No	[REDACTED]
[REDACTED]	No	[REDACTED]
[REDACTED]	Yes	[REDACTED]
[REDACTED]	Yes	[REDACTED]
[REDACTED]	No	[REDACTED]
[REDACTED]	No	[REDACTED]
[REDACTED]	Yes	[REDACTED]
[REDACTED]	No	[REDACTED]
[REDACTED]	Yes	[REDACTED]
[REDACTED]	No	[REDACTED]
[REDACTED]	No	[REDACTED]
[REDACTED]	No	[REDACTED]
[REDACTED]	Yes	[REDACTED]
[REDACTED]	Yes	[REDACTED]

**Cell Lines**  
**Cell Line**

**Cell Lines Administered to Animals in Vivo**



## Microbial Agents

[REDACTED] No  
Biosafety Level : BSL2  
Meeting Notes : The amendment adds two new [REDACTED] and one gene for in vitro work. Two human [REDACTED] will be administered to animals, and number of one IACUC protocol was updated.

---

Disposition	Votes For	Votes Against	Votes Abstain	Votes-Recuse
Approved With Contingencies	25	0	0	0

Investigator : Simone Krebs  
Document No. : [RM00007946-RN00\\_AM7](#)  
NIH Guidelines Category : III-D-1-a.  
Agents :

## Non Viral Systems

Technical Name	Is Whole Animal Used as Host
PcDNA-KLG3	No
SFG-KLG3-BBZ-P2A-C825	No

## Viral Systems

Virus System	Virus Administered to Animals	Backbones
Lentivirus	No	SFG
Retrovirus	No	SFG

## Cell Lines

Cell Line	Cell Lines Administered to Animals in Vivo
Galv9	No
human embryonic kidney cells	No
Murine lymphocytes (derived from peripheral blood and tissue mononuclear cells)	Yes
genetically engineered Human T cells expressing CAR and/or anti-DOTAscFv	Yes
Phoenix ECO	No
Human lymphocytes (derived from peripheral blood and tissue mononuclear cells)	Yes
genetically engineered murine T cells expressing CAR and/or anti-DOTAscFv	Yes

## Microbial Agents

Name	Administered to Animals in Vivo
E. coli DH5 $\alpha$	No

Biosafety Level : BSL2  
Meeting Notes : They added a lentiviral system to the protocol.

---

Disposition	Votes For	Votes Against	Votes Abstain	Votes-Recuse
Approved With Contingencies	25	0	0	0

Investigator : Guillermina Lozano  
Document No. : [RM00000681-RN02\\_AM3](#)  
NIH Guidelines Category : III-D-4-b.  
Agents :

**Non Viral Systems****Technical Name**

pCEP

pVSVG

**Is Whole Animal Used as Host**

No

No

**Viral Systems****Virus System**

lentivirus

Lentivirus

AAV

lentivirus

retroviruses

Lentivirus

adenovirus

**Virus Administered to Animals**

Yes

Yes

Yes

Yes

No

No

Yes

**Backbones**

pGIPZ, pLOC

pLenti

Av8

pLentiCRISPRv2, pLentiGuidePuro

pBABE

mTKOv3

Ad5

**Cell Lines****Cell Line**

mammary gland ducts

murine breast cancer cell lines

breast cancer cell line MCF10A

human embryonic kidney 293T cells

breast cancer tissue

Osteosarcoma cells SaOs2

osteosarcoma cell lines

mouse embryo fibroblasts

**Cell Lines Administered to Animals in Vivo**

No

Yes

No

No

No

Yes

Yes

No

**Microbial Agents****Name**

E. coli Stb13

Biosafety Level :

Meeting Notes :

**Administered to Animals in Vivo**

No

BSL2

Updated IACUC protocol due to renewal.

<b>Disposition</b>	<b>Votes For</b>	<b>Votes Against</b>	<b>Votes Abstain</b>	<b>Votes-Recuse</b>
Approved With Contingencies	25	0	0	0

Investigator :

Peter Grace

Document No. :

[RM00003601-RN01\\_AM14](#)

NIH Guidelines Category :

III-D-4-b.

Agents :

**Non Viral Systems****Technical Name**

pcDNA3.1

pGL4.32

pFlag-CMV

pcDNA3-YFP

pcDNA3

pRL-CMV

shRNA (U6 promoter Tie2-targeted ST6Gal1)

shRNA missense control

**Is Whole Animal Used as Host**

No

No

No

No

No

No

Yes

Yes

## Viral Systems

Virus System	Virus Administered to Animals	Backbones
Lentivirus	No	LV
Lentivirus	No	lentiCRISPR v2
adeno associated virus	Yes	AAV
Human herpesvirus 1	Yes	HSV-1

## Cell Lines

Cell Line	Cell Lines Administered to Animals in Vivo
Caco-2 epithelial cells from colon tissue	No
NRF2/ARE Luciferase Reporter human embryonic kidney - HEK293	No
50B11 (DRG-derived cell line)	No
Rat cortical astrocytes	Yes
HuTu 80 epithelial cells from small intestine	No
Human small intestine epithelial cells	No

## Microbial Agents

Name	Administered to Animals in Vivo
E.coli DH5 $\alpha$	No
Biosafety Level :	BSL2
Meeting Notes :	They added shRNA constructs for in vivo administration.

---

Disposition	Votes For	Votes Against	Votes Abstain	Votes-Recuse
Approved	25	0	0	0

Investigator : Benjamin Schrank  
Document No. : [RM00008251-RN00\\_AM3](#)  
NIH Guidelines Category : III-D-4-b.  
Agents :

## Viral Systems

Virus System	Virus Administered to Animals	Backbones
Retrovirus	No	MSCV, pQCXIN, pBABE puro
Lentivirus	No	pBOB
Adenovirus	Yes	pBR322

## Cell Lines

Cell Line	Cell Lines Administered to Animals in Vivo
EO771	Yes
PC3	No
CT26	Yes
4T1	Yes
MC38	Yes
Biosafety Level :	BSL2
Meeting Notes :	Amendment includes adding a retrovirus system as well as two mouse lines and one human line.

---

Disposition	Votes For	Votes Against	Votes Abstain	Votes-Recuse
Approved With Contingencies	25	0	0	0

Investigator : Daoyan Wei

Document No. : RM00002985-RN01\_AM5

NIH Guidelines Category : III-D-1-a.

Agents :

### Non Viral Systems

Technical Name	Is Whole Animal Used as Host
pcDNA3.1	No
pEGFP	No

### Viral Systems

Virus System	Virus Administered to Animals	Backbones
Lentivirus	No	pLVX-shRNA1
Lentivirus	No	Lenti-Cas9-2A-Blast
Lentivirus	No	pLVX
Adenovirus	No	pAdeasy

### Cell Lines

Cell Line	Cell Lines Administered to Animals in Vivo
gastric cancer	Yes
liver cancer	Yes
pancreatic acinar cells	No
Pancreatic cancer	Yes

### Microbial Agents

Name	Administered to Animals in Vivo
E. coli DH5-alpha	No

Biosafety Level : BSL2

Meeting Notes : Updated IACUC protocol numbers due to renewal.

---

Disposition	Votes For	Votes Against	Votes Abstain	Votes-Recuse
Approved With Contingencies	24	0	1	0

Investigator : Vidya Gopalakrishnan

Document No. : RM00001584-RN01\_AM1

NIH Guidelines Category : III-D-1-a.

Agents :

### Viral Systems

Virus System	Virus Administered to Animals	Backbones
Lentivirus	No	P-VSVG
Lentivirus	No	psPAX2
Lentivirus	No	pGipZ

### Cell Lines

Cell Line	Cell Lines Administered to Animals in Vivo
Human Kidney Cancer Cells	No
Brain Cancer	Yes

### Microbial Agents

Name	Administered to Animals in Vivo
E.coli K-12	No

Biosafety Level : BSL2

Meeting Notes : Updated IACUC protocol number due to renewal.

---

Disposition	Votes For	Votes Against	Votes Abstain	Votes-Recuse
Approved With Contingencies	24	0	1	0

Investigator : Vidya Gopalakrishnan  
Document No. : [RM00001327-RN02\\_AM1](#)  
NIH Guidelines Category : III-D-1-a.  
Agents :

**Viral Systems**

Virus System	Virus Administered to Animals	Backbones
Lentivirus	No	pGIPZ

**Cell Lines**

Cell Line	Cell Lines Administered to Animals in Vivo
293T cell (embryonic kidney of Homo sapiens)	No
Brain Cancer	Yes

**Microbial Agents**

Name	Administered to Animals in Vivo
E.coli dh5 alpha	No
Biosafety Level :	BSL2
Meeting Notes :	Updated IACUC protocol number due to renewal.

Disposition	Votes For	Votes Against	Votes Abstain	Votes-Recuse
Approved	25	0	0	0

Investigator : Jian Hu  
Document No. : [RM00000880-RN02\\_AM5](#)  
NIH Guidelines Category : III-D-4-b.  
Agents :

**Non Viral Systems**

Technical Name	Is Whole Animal Used as Host
[REDACTED]	No
[REDACTED]	No
[REDACTED]	No
[REDACTED]	No
[REDACTED]	No
[REDACTED]	No
[REDACTED]	No
[REDACTED]	No
[REDACTED]	No

**Viral Systems**

Virus System	Virus Administered to Animals	Backbones
[REDACTED]	No	[REDACTED]
[REDACTED]	No	[REDACTED]
[REDACTED]	No	[REDACTED]
[REDACTED]	No	[REDACTED]
[REDACTED]	No	[REDACTED]
[REDACTED]	Yes	[REDACTED]
[REDACTED]	No	[REDACTED]
[REDACTED]	No	[REDACTED]
[REDACTED]	Yes	[REDACTED]



**Cell Lines**

**Cell Line**

Brain Cancer

Human Kidney Cancer Cells (293T)

**Cell Lines Administered to Animals in Vivo**

Yes

No

**Microbial Agents**

**Name**

E.coli K-12

**Administered to Animals in Vivo**

No

Biosafety Level :

BSL2

Meeting Notes :

Updated IACUC protocol number due to renewal.

**8. ADMINISTRATIVE MODIFICATIONS**

**Disposition**

**Votes For**

**Votes Against**

**Votes Abstain**

**Votes-Recuse**

Approved

25

0

0

0

Investigator :

Sattva S Neelapu

Document No. :

[RM00000070-RN02\\_AM4](#)

NIH Guidelines Category :

Agents :

**Non Viral Systems**

**Technical Name**

[REDACTED]

**Is Whole Animal Used as Host**

No

**Viral Systems**

**Virus System**

[REDACTED]

**Virus Administered to Animals**

No

[REDACTED]

No

[REDACTED]

No

[REDACTED]

No

**Backbones**

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

**Cell Lines**

**Cell Line**

[REDACTED]

**Cell Lines Administered to Animals in Vivo**

Yes

[REDACTED]

Yes

[REDACTED]

No

[REDACTED]

Yes

[REDACTED]

No

[REDACTED]

Yes

[REDACTED]

Yes

[REDACTED]

Yes

**Microbial Agents**

**Name**

[REDACTED]

**Administered to Animals in Vivo**

No

Biosafety Level :

BSL2

Meeting Notes :

Personnel changes only.

**Disposition**

**Votes For**

**Votes Against**

**Votes Abstain**

**Votes-Recuse**

Approved

25

0

0

0

Investigator : Xiling Shen  
 Document No. : RM00007541-RN00\_AM11  
 NIH Guidelines Category :  
 Agents :

**Non Viral Systems**

<b>Technical Name</b>	<b>Is Whole Animal Used as Host</b>
pcDNA3	No
pEGFP	No

**Viral Systems**

<b>Virus System</b>	<b>Virus Administered to Animals</b>	<b>Backbones</b>
Lentivirus	No	pLVX
Lentivirus	No	pKLV

**Cell Lines**

<b>Cell Line</b>	<b>Cell Lines Administered to Animals in Vivo</b>
Colon	Yes
OT-I CD8+ T cells.	No
Patient derived colon tissue	Yes
Colon patient derived xenograft	Yes
OTII CD4+ T cells.	No
MC38-Ova Cell line	No
Colon patient derived xenograft	Yes
PBMC	No
Colon cell line	Yes

**Microbial Agents**

<b>Name</b>	<b>Administered to Animals in Vivo</b>
E.coli DH5alpha	No
Biosafety Level :	BSL2
Meeting Notes :	Personnel changes only.

<b>Disposition</b>	<b>Votes For</b>	<b>Votes Against</b>	<b>Votes Abstain</b>	<b>Votes-Recuse</b>
Approved	25	0	0	0

Investigator : George A Calin  
 Document No. : RM00000218-RN02\_AM5  
 NIH Guidelines Category :  
 Agents :

**Non Viral Systems**

<b>Technical Name</b>	<b>Is Whole Animal Used as Host</b>
p-cDNA3.1 (empty vector or gene sequence inserted: CCAT2)	No
pMS2	No
pMS2+Luc147	No
pMS2-GST	No

**Viral Systems**

<b>Virus System</b>	<b>Virus Administered to Animals</b>	<b>Backbones</b>
Retroviral Vector	No	pSR-GFP-Neo (OligoEngine, Seattle, WA); gene sequence inserted: CCAT2
Adenovirus	Yes	virus particles with a cytomegalovirus (CMV) promoter following with the CRE

## Viral Systems

Lentivirus	No	pCDH-CMV-MCS-EF1-copGFP-T2A-Puro
Lentivirus	No	pMIRNA1 lentiviral vector (System Bioscience)
Retrovirus vector	No	pBABE-puro (Addgene, Cambridge, MA); gene sequence inserted: CCAT2

## Cell Lines

Cell Line	Cell Lines Administered to Animals in Vivo
primary monocytes	Yes
A673 Ewing Sarcoma	Yes
HUMAC mammary epithelial cell line	No
CAMA-1 breast cancer cell line	No
MCF7 breast cancer cell line	No
T47D breast cancer cell line	No
Prostate cancer	Yes
HCT116 colon cancer cell line	No
293T cells	No
A549-luc lung cancer cell line	Yes

## Microbial Agents

Name	Administered to Animals in Vivo
Escherichia coli serotype B7-086a:K61	No
Biosafety Level :	BSL2
Meeting Notes :	Personnel changes only.

---

Disposition	Votes For	Votes Against	Votes Abstain	Votes-Recuse
Approved	24	0	1	0

Investigator : Marcos Roberto Estecio  
Document No. : [RM00000418-RN02\\_AM2](#)  
NIH Guidelines Category :  
Agents :

## Non Viral Systems

Technical Name	Is Whole Animal Used as Host
pCMV6-Entry	No
p3xFLAG CMV14 / BRAF-V600E	No
pCIneo-hCHD7-Kozak ATG	No
pSpCas9(BB)-2A-GFP (PX458)	No

## Viral Systems

Virus System	Virus Administered to Animals	Backbones
Lentivirus	No	pMD2.G; psPAX2; TRC2-pLKO-puro; PLenti-C-Myc-DDK-IRES-Puro; pLX307; pHAGE-BRAF-V600E

## Cell Lines

Cell Line	Cell Lines Administered to Animals in Vivo
human embryonic kidney (293FT)	No
Colon cancer cell lines (HCT15, SW620, DLD-1, HT29)	No
Colon cell line (CCD 841CoN)	No

## Microbial Agents

**Name** **Administered to Animals in Vivo**  
E. coli DH5a No  
Biosafety Level : BSL2  
Meeting Notes : Personnel changes only.

---

Disposition	Votes For	Votes Against	Votes Abstain	Votes-Recuse
Approved	25	0	0	0

Investigator : Simone Krebs  
Document No. : [RM00007946-RN00\\_AM5](#)  
NIH Guidelines Category :  
Agents :

## Non Viral Systems

**Technical Name** **Is Whole Animal Used as Host**  
PcDNA-KLG3 No  
SFG-KLG3-BBZ-P2A-C825 No

## Viral Systems

Virus System	Virus Administered to Animals	Backbones
Retrovirus	No	SFG

## Cell Lines

Cell Line	Cell Lines Administered to Animals in Vivo
human embryonic kidney cells	No
Murine lymphocytes (derived from peripheral blood and tissue mononuclear cells)	Yes
genetically engineered Human T cells expressing CAR and/or anti-DOTAscFv	Yes
Galv9	No
Phoenix ECO	No
Human lymphocytes (derived from peripheral blood and tissue mononuclear cells)	Yes
genetically engineered murine T cells expressing CAR and/or anti-DOTAscFv	Yes

## Microbial Agents

**Name** **Administered to Animals in Vivo**  
E. coli DH5 $\alpha$  No  
Biosafety Level : BSL2  
Meeting Notes : Personnel changes only.

---

Disposition	Votes For	Votes Against	Votes Abstain	Votes-Recuse
Approved	24	0	1	0

Investigator : Vidya Gopalakrishnan  
Document No. : [RM00001327-RN02\\_AM2](#)  
NIH Guidelines Category :  
Agents :

## Viral Systems

Virus System	Virus Administered to Animals	Backbones
Lentivirus	No	pGIPZ

## Cell Lines

### Cell Line

293T cell (embryonic kidney of Homo sapiens)

Brain Cancer

### Cell Lines Administered to Animals in Vivo

No

Yes

## Microbial Agents

### Name

E.coli dh5 alpha

Biosafety Level :

Meeting Notes :

### Administered to Animals in Vivo

No

BSL2

Personnel changes only.

---

### Disposition

#### Votes For

#### Votes Against

#### Votes Abstain

#### Votes-Recuse

Approved

25

0

0

0

Investigator :

Document No. :

NIH Guidelines Category :

Agents :

Chandra Bartholomeusz

[RM00004881-RN00\\_AM4](#)

## Viral Systems

### Virus System

Lentivirus

### Virus Administered to Animals

No

### Backbones

pGFP-V-RS

## Cell Lines

### Cell Line

Breast Cancer

### Cell Lines Administered to Animals in Vivo

Yes

## Microbial Agents

### Name

E.coli DH5alpha

Biosafety Level :

Meeting Notes :

### Administered to Animals in Vivo

No

BSL2

Personnel changes only.

---

### Disposition

#### Votes For

#### Votes Against

#### Votes Abstain

#### Votes-Recuse

Approved

25

0

0

0

Investigator :

Document No. :

NIH Guidelines Category :

Agents :

Simone Krebs

[RM00007946-RN00\\_AM6](#)

## Non Viral Systems

### Technical Name

PcDNA-KLG3

SFG-KLG3-BBZ-P2A-C825

### Is Whole Animal Used as Host

No

No

## Viral Systems

### Virus System

Retrovirus

### Virus Administered to Animals

No

### Backbones

SFG

## Cell Lines

### Cell Line

human embryonic kidney cells

Murine lymphocytes (derived from peripheral blood and tissue mononuclear cells)

### Cell Lines Administered to Animals in Vivo

No

Yes

## Cell Lines

genetically engineered Human T cells expressing CAR and/or anti-DOTAscFv	Yes
Galv9	No
Phoenix ECO	No
Human lymphocytes (derived from peripheral blood and tissue mononuclear cells)	Yes
genetically engineered murine T cells expressing CAR and/or anti-DOTAscFv	Yes

## Microbial Agents

Name	Administered to Animals in Vivo
E. coli DH5 $\alpha$	No
Biosafety Level :	BSL2
Meeting Notes :	Personnel changes only.

---

Disposition	Votes For	Votes Against	Votes Abstain	Votes-Recuse
Approved	24	0	1	0

Investigator : Humam N Kadara  
Document No. : [RM00003627-RN01\\_AM10](#)  
NIH Guidelines Category :  
Agents :

## Non Viral Systems

Technical Name	Is Whole Animal Used as Host
CD24 HDR plasmid (non-viral, co-transfected for puromycin selection)	No
Control CRISPR/Cas9 Plasmid	No
CD24 CRISPR/Cas9 Knockout (KO) plasmid (guide RNA)	No

## Viral Systems

Virus System	Virus Administered to Animals	Backbones
Adeno-associated virus serotype 6	Yes	Recombinant AAV
Adeno-associated virus serotype 5	Yes	Recombinant AAV
adenovirus Ad5mSPC-Cre-eGFP	Yes	pacAd5(9.2-100)sub360 viral backbone
adeno associated virus	Yes	sc-CMV
Lentivirus	No	pGIPZ
adenovirus Ad5mSPC-nteGFP	Yes	pacAd5(9.2-100)sub360 viral backbone
adenovirus Ad5mSPC-FLPo	Yes	pacAd5(9.2-100)sub360 viral backbone.
adenovirus Ad5CMVFLPO	Yes	pacAd5(9.2-100)sub360 viral backbone
Lentivirus	No	pLenti CMV V5-LUC
Ad5-hK14/Bgi-Cre	Yes	pacAd5(9.2-100)sub360 viral backbone

## Cell Lines

Cell Line	Cell Lines Administered to Animals in Vivo
Lung cancer cell line - 344SQ	Yes
FVBW-17 (gRNA control) - Mouse lung cancer cell-line	Yes
FM471-ctrl-gRNA-GFP/luciferase cells	Yes
293FT cells	No
LKR-13 Luciferase/GFP stable cells - Mouse lung cancer cell-line	Yes

## Cell Lines

mF471-CD24-gRNA-GFP/luciferase cells - mouse lung cancer cells	Yes
LKR-13(gRNA control) - Mouse lung cancer cell-line	Yes
FVBW-17 (CD24-gRNA) - Mouse lung cancer cell-line	Yes
Fvbw 17-GFP/luciferase cells - mouse lung cancer cells	Yes
LKR-13 (Mouse lung cancer cell-line)	Yes
mF471 Luciferase/GFP stable cells - mouse lung cancer cells	Yes
mF471 - mouse lung cancer cells	Yes
LKR-13 (CD24-gRNA) - Mouse lung cancer cell-line	Yes
FVBW-17 cells (Mouse lung cancer cells)	Yes
393P (Mouse lung cancer cell-line)	Yes

## Microbial Agents

Name	Administered to Animals in Vivo
Influenza A	Yes
Sendai virus	Yes
DH5a cells	No
Biosafety Level :	BSL2
Meeting Notes :	Personnel changes only.

---

Disposition	Votes For	Votes Against	Votes Abstain	Votes-Recuse
Approved	25	0	0	0

Investigator :

Guillermina Lozano

Document No. :

[RM00000681-RN02\\_AM4](#)

NIH Guidelines Category :

Agents :

## Non Viral Systems

Technical Name	Is Whole Animal Used as Host
pCEP	No
pVSVG	No

## Viral Systems

Virus System	Virus Administered to Animals	Backbones
retroviruses	No	pBABE
lentivirus	Yes	pLentiCRISPRv2, pLentiGuidePuro
Lentivirus	No	mTKOv3
Lentivirus	Yes	pLenti
lentivirus	Yes	pGIPZ, pLOC
AAV	Yes	Av8
adenovirus	Yes	Ad5

## Cell Lines

Cell Line	Cell Lines Administered to Animals in Vivo
mouse embryo fibroblasts	No
breast cancer tissue	No
breast cancer cell line MCF10A	No
murine breast cancer cell lines	Yes
osteosarcoma cell lines	Yes
human embryonic kidney 293T cells	No

### Cell Lines

Osteosarcoma cells SaOs2 Yes  
mammary gland ducts No

### Microbial Agents

**Name** **Administered to Animals in Vivo**  
E. coli Stb13 No  
Biosafety Level : BSL2  
Meeting Notes : Personnel changes only.

---

Disposition	Votes For	Votes Against	Votes Abstain	Votes-Recuse
Approved	24	0	1	0

Investigator : Vidya Gopalakrishnan  
Document No. : [RM00000959-RN02\\_AM2](#)  
NIH Guidelines Category :  
Agents :

### Viral Systems

Virus System	Virus Administered to Animals	Backbones
Lentivirus	No	P-VSVG
Lentivirus	No	psPAX2
Lentivirus	No	pLKO

### Cell Lines

**Cell Line** **Cell Lines Administered to Animals in Vivo**  
Mouse neural progenitor cells Yes  
293T No

### Microbial Agents

**Name** **Administered to Animals in Vivo**  
E.coli, DH5a No  
Biosafety Level : BSL2  
Meeting Notes : Personnel changes only.

---

Disposition	Votes For	Votes Against	Votes Abstain	Votes-Recuse
Approved	25	0	0	0

Investigator : Sarah Kezar  
Document No. : [RM00006297-RN00\\_AM10](#)  
NIH Guidelines Category :  
Agents :

### Cell Lines

**Cell Line** **Cell Lines Administered to Animals in Vivo**  
Plasma in Acid Citrate Dextrose (ACD) or citrate phosphate dextrose adenine 1 (CPDA-1) anticoagulant Yes

### Microbial Agents

**Name** **Administered to Animals in Vivo**  
Human Immunodeficiency Virus-1 (HIV-1) CH077 backbone "077\_RMT" Yes  
Human Immunodeficiency Virus-1 (HIV-1) CH077 backbone "077\_RMTE" Yes

## Microbial Agents

Human Immunodeficiency Virus-1 (HIV-1) CH077 backbone "077\_RM" Yes  
Human immunodeficiency virus-1 NL4-3 backbone Yes  
Human Immunodeficiency Virus-1 (HIV-1) CH077 backbone "077\_R" Yes  
Human Immunodeficiency Virus-1 (HIV-1) CH077 backbone "077\_RTE" Yes

Biosafety Level : BSL2

Meeting Notes : Personnel changes only.

---

Disposition	Votes For	Votes Against	Votes Abstain	Votes-Recuse
Approved	25	0	0	0

Investigator : Guillermina Lozano

Document No. : [RM00000681-RN02\\_AM5](#)

NIH Guidelines Category :

Agents :

## Non Viral Systems

Technical Name	Is Whole Animal Used as Host
pCEP	No
pVSVG	No

## Viral Systems

Virus System	Virus Administered to Animals	Backbones
retroviruses	No	pBABE
lentivirus	Yes	pLentiCRISPRv2, pLentiGuidePuro
Lentivirus	No	mTKOv3
Lentivirus	Yes	pLenti
lentivirus	Yes	pGIPZ, pLOC
AAV	Yes	Av8
adenovirus	Yes	Ad5

## Cell Lines

Cell Line	Cell Lines Administered to Animals in Vivo
mouse embryo fibroblasts	No
breast cancer tissue	No
breast cancer cell line MCF10A	No
murine breast cancer cell lines	Yes
osteosarcoma cell lines	Yes
human embryonic kidney 293T cells	No
Osteosarcoma cells SaOs2	Yes
mammary gland ducts	No

## Microbial Agents

Name	Administered to Animals in Vivo
E. coli Stb13	No

Biosafety Level : BSL2

Meeting Notes : Personnel changes only.

---

Disposition	Votes For	Votes Against	Votes Abstain	Votes-Recuse
Approved	24	0	1	0

Investigator : Vidya Gopalakrishnan  
 Document No. : RM00001584-RN01\_AM2  
 NIH Guidelines Category :  
 Agents :

**Viral Systems**

Virus System	Virus Administered to Animals	Backbones
Lentivirus	No	P-VSVG
Lentivirus	No	pGipZ
Lentivirus	No	psPAX2

**Cell Lines**

Cell Line	Cell Lines Administered to Animals in Vivo
Brain Cancer	Yes
Human Kidney Cancer Cells	No

**Microbial Agents**

Name	Administered to Animals in Vivo
E.coli K-12	No
Biosafety Level :	BSL2
Meeting Notes :	Personnel changes only.

Disposition	Votes For	Votes Against	Votes Abstain	Votes-Recuse
Approved	24	0	1	0

Investigator : Vidya Gopalakrishnan  
 Document No. : RM00000443-RN02\_AM2  
 NIH Guidelines Category :  
 Agents :

**Non Viral Systems**

Technical Name	Is Whole Animal Used as Host
HA-ubiquitin	No
pcDNA3-myc3-p27	No
pcDNA3-myc-Skp2	No
ffluc/mKate	No
pcDNA3.1/ND2/REST	No
Flag-HA-USP37 C234S (mut)	No
pBeta-TRCP	No
Flag-HA-USP1	No
pcDNA3.1/ND2/REST	No
Flag-HA-USP37	No

**Viral Systems**

Virus System	Virus Administered to Animals	Backbones
Lentiviral	No	pLKO.1 shRNA vector
Lentivirus	No	pLX304-PRMT8
Lentivirus	No	Puro.Cre
Retrovirus	No	MigR1-REST-VP16;MigR1-REST C-term mut;Migr1-REST N-term mut
Retrovirus	No	pMSCVpuro
Lentivirus	No	pGIPZ lentiviral vector, shG9a, shHDAC1, shHDC2, shLSD1, shP27,





**Viral Systems**

[Redacted]

No  
No  
No  
No  
No  
No  
No

[Redacted]

[Redacted]

No  
No  
No  
No

**Cell Lines**

**Cell Line**

[Redacted]

**Cell Lines Administered to Animals in Vivo**

Yes  
Yes  
No  
Yes  
Yes  
No  
No  
Yes  
Yes  
Yes  
Yes  
No

**Microbial Agents**

**Name**

[Redacted]

**Administered to Animals in Vivo**

No  
No  
No  
No  
No

Biosafety Level :

BSL2

Meeting Notes :

Personnel changes only.

Disposition	Votes For	Votes Against	Votes Abstain	Votes-Recuse
Approved	25	0	0	0

Investigator :

Xiling Shen

Document No. :

[RM00007541-RN00\\_AM10](#)

NIH Guidelines Category :

Agents :

**Non Viral Systems**

**Technical Name**

pcDNA3  
pEGFP

**Is Whole Animal Used as Host**

No  
No

**Viral Systems****Virus System**

Lentivirus

**Virus Administered to Animals**

No

**Backbones**

pLVX

Lentivirus

No

pKLV

**Cell Lines****Cell Line**

Colon

**Cell Lines Administered to Animals in Vivo**

Yes

OT-I CD8+ T cells.

No

Patient derived colon tissue

Yes

Colon patient derived xenograft

Yes

OTII CD4+ T cells.

No

MC38-Ova Cell line

No

Colon patient derived xenograft

Yes

PBMC

No

Colon cell line

Yes

**Microbial Agents****Name**

E.coli DH5alpha

**Administered to Animals in Vivo**

No

Biosafety Level :

BSL2

Meeting Notes :

Personnel changes only.

**Disposition****Votes For****Votes Against****Votes Abstain****Votes-Recuse**

Approved

25

0

0

0

Investigator :

Dejka Marida Araujo

Document No. :

[RM00003152-RN01\\_AM2](#)

NIH Guidelines Category :

Agents :

**Viral Systems****Virus System**

[REDACTED]

**Virus Administered to Animals**

No

**Backbones**

[REDACTED]

**Cell Lines****Cell Line**

[REDACTED]

**Cell Lines Administered to Animals in Vivo**

No

Biosafety Level :

BSL2

Meeting Notes :

Personnel changes only.

**Disposition****Votes For****Votes Against****Votes Abstain****Votes-Recuse**

Approved

25

0

0

0

Investigator :

Emily Keung

Document No. :

[RM00006821-RN00\\_AM14](#)

NIH Guidelines Category :

Agents :

**Non Viral Systems****Technical Name**

pLKO-RFP-shCntrl

**Is Whole Animal Used as Host**

No

## Viral Systems

### Virus System

lentivirus

### Virus Administered to Animals

No

### Backbones

pLKO.1

## Cell Lines

### Cell Line

Sarcoma

### Cell Lines Administered to Animals in Vivo

Yes

Sarcoma

Yes

HEK293

Yes

SKBP

Yes

CCNE1

Yes

MCA205

Yes

Buffy coat

No

Macrophages

No

Lymphocytes (T cells, B cells, NK cells)

No

Sarcoma

Yes

Dendritic cells

No

Biosafety Level :

BSL2

Meeting Notes :

Personnel changes only.

---

### Disposition

### Votes For

### Votes Against

### Votes Abstain

### Votes-Recuse

Approved

24

0

1

0

Investigator :

Vidya Gopalakrishnan

Document No. :

[RM00001918-RN01\\_AM4](#)

NIH Guidelines Category :

Agents :

## Non Viral Systems

### Technical Name

pX458-U6-chimeric BB(+85)-CBh-NLS-hSpCsn1-2A-GFP

### Is Whole Animal Used as Host

No

pGL4.20

No

## Viral Systems

### Virus System

Lentivirus

### Virus Administered to Animals

No

### Backbones

Phage-ef1a-ccdb-ires-Flu2-mkat2

Lentivirus

No

Phage-ef1a-ccdb-ires-puro

Lentivirus

No

Phage-ef1a-ccdb-ires-mkate2

Lentivirus

No

Phage-ef1a-ccdb-ires-Flu2-GFP

Lentivirus

No

pGIPZ

Lentivirus

No

Phage-ef1a-ccdb-ires-Renilla-GFP

Lentivirus

No

pLTR-RD114A

Lentivirus

No

pHCMV\_Bless

Lentivirus

No

P-VSVG

Retrovirus

No

mimR1-Flu2-mkate2

Retrovirus

No

mipR1-Flu2-puro

Lentivirus

No

Phage-ef1a-ccdb-ires-GFP

## Cell Lines

### Cell Line

293T cell (embryonic kidney of Homo sapiens)

No

### Cell Lines Administered to Animals in Vivo

Brain Cancer

Yes

**Cell Lines**

Neural Stem Cells and Progenitors Yes

**Microbial Agents**

Name	Administered to Animals in Vivo
E.coli, DH5a	No
E. coli k-12	No
Biosafety Level :	BSL2
Meeting Notes :	Personnel changes only.

---

**9. ANNUAL REVIEWS**

25=yes; 0=no; 0-abstain; 0-recuse

Investigator : Edwin Justin Ostrin  
Document No. : [RM00004002-RN01\\_AR001](#)

---

Investigator : Zhen Fan  
Document No. : [RM00000145-RN02\\_AR004](#)

---

Investigator : Nitin Jain  
Document No. : [RM00002765-RN01\\_AR003](#)

---

Investigator : Jason Schenkel  
Document No. : [RM00006304-RN00\\_AR003](#)

---

Investigator : Kunal Rai  
Document No. : [TA00000878-RN02\\_AR001](#)

---

Investigator : Steven Jay Frank  
Document No. : [RM00003665-RN01\\_AR002](#)

---

Investigator : Sattva S Neelapu  
Document No. : [RM00000070-RN02\\_AR001](#)

---

Investigator : Omar Pacha  
Document No. : [RM00007170-RN00\\_AR002](#)

---

Investigator : Isabella Claudia Glitza Oliva  
Document No. : [RM00008002-RN00\\_AR001](#)

---

Investigator : Jennifer Wargo  
Document No. : [RM00002193-RN01\\_AR004](#)

---

Investigator : Lawrence Kwong  
Document No. : [RM00002361-RN01\\_AR004](#)

---

Investigator : Shengqing Gu  
Document No. : [RM00006354-RN00\\_AR003](#)

---

Investigator : Ecaterina Ileana Dumbrava  
Document No. : [RM00007296-RN00\\_AR002](#)

---

Investigator : Gohar Manzar  
Document No. : [RM00007994-RN00\\_AR001](#)

---

Investigator : Stephanie S Watowich  
Document No. : [RM00000293-RN03\\_AR001](#)

---

Investigator : Pablo C Okhuysen  
Document No. : [RM00006274-RN00\\_AR003](#)

---

Investigator : Christopher Johnston  
Document No. : [RM00007966-RN00\\_AR001](#)

---

Investigator : Chitra Hosing  
Document No. : [RM00007277-RN00\\_AR002](#)

---

Investigator : Uday R Popat  
Document No. : [RM00008043-RN00\\_AR001](#)

---

Investigator : Yu Lei  
Document No. : [RM00007339-RN00\\_AR002](#)

---

Investigator : Robert Orłowski  
Document No. : [RM00006334-RN00\\_AR003](#)

---

Investigator : John Victor Heymach  
Document No. : [RM00000523-RN02\\_AR002](#)

---

Investigator : Sarah Kezar  
Document No. : [RM00006297-RN00\\_AR003](#)

---

Investigator : Dimitrios P Kontoyiannis  
Document No. : [RM00003639-RN01\\_AR002](#)

---

Investigator : Lei Nie  
Document No. : [RM00006355-RN00\\_AR003](#)

---

Investigator : Kunal Rai  
Document No. : [RM00000815-RN02\\_AR001](#)

---

Investigator : Sarina Anne Piha-Paul  
Document No. : [RM00007059-RN00\\_AR002](#)

---

Investigator : Powel H Brown  
Document No. : [RM00000548-RN02\\_AR003](#)

---

Investigator : Gabriel Pagnotti  
Document No. : [RM00006218-RN00\\_AR003](#)

---

Investigator : Elizabeth Shpall  
Document No. : [RM00000328-RN02\\_AR003](#)

---

Investigator : Guocan Wang  
Document No. : [RM00002407-RN01\\_AR004](#)

---

Investigator : Michael J Galko  
Document No. : [RM00000648-RN02\\_AR003](#)

---

Investigator : Powel H Brown  
Document No. : [RM00000549-RN02\\_AR001](#)

---

Investigator : Waldemar Priebe  
Document No. : [RM00006409-RN00\\_AR003](#)

---

Investigator : Kwong K Wong

Document No. : [RM00000428-RN02\\_AR003](#)

---

Investigator : Claudio M Aldaz

Document No. : [RM00007274-RN00\\_AR002](#)

---

Investigator : Krina Patel

Document No. : [RM00007119-RN00\\_AR002](#)

---

Investigator : David Piwnica-Worms

Document No. : [RM00000156-RN02\\_AR002](#)

---

Investigator : Eugenie S Kleinerman

Document No. : [RM00000459-RN02\\_AR004](#)

---

Investigator : Michael J Galko

Document No. : [TA00002968-RN01\\_AR003](#)

---

Investigator : Shawn B Bratton

Document No. : [RM00000258-RN02\\_AR004](#)

---

Investigator : Johannes Francois Fahrman

Document No. : [RM00006472-RN00\\_AR003](#)

---

Investigator : Rugang Zhang

Document No. : [RM00006425-RN00\\_AR003](#)

---

Investigator : Rugang Zhang

Document No. : [TA00006499-RN00\\_AR003](#)

---

Investigator : Sonal Noticewala

Document No. : [RM00008053-RN00\\_AR001](#)

---

Investigator : Apar Pataer

Document No. : [RM00005690-RN00\\_AR004](#)

---

## 10. TERMINATIONS

25=yes; 0=no; 0-abstain; 0-recuse

Investigator : David Sanghyun Hong

Document No. : [RM00005106-RN00](#)

---

Investigator : Eugenie S Kleinerman

Document No. : [RM00005021-RN00](#)

---

Investigator : Gregory A Lizee

Document No. : [RM00005711-RN00](#)

---

Investigator : Gregory A Lizee

Document No. : [RM00005562-RN00](#)

---

Investigator : Daoyan Wei

Document No. : [TA00002994-RN01](#)

---

## 11. OLD BUSINESS ITEMS

Item	Description	Presenter	Attachments
Update: Region 4 (SBA region) Listening Session for Modernizing		Chavaun H. LeBlanc, M.S.; Mgr, Environ Health & Safety, Fac	

and Strengthening  
Oversight of Biosafety

Mgt EHS EPP Lab &  
OHS

**12. NEW BUSINESS ITEMS**

There are no such business items for this meeting.

**13. DISCUSSION ITEMS**

There are no such business items for this meeting.

**14. INFORMATIONAL ITEMS**

**Update**

Community Member Attendance

**Description**

Manu Banadakoppa was not in attendance. Arlisa Edwards-Benford was present and counted among the votes.

**15. ADJOURNMENT**